Safety and Efficacy of PD-1/PD-L1 Inhibitors in Cancer Patients With Preexisting Autoantibodies

BackgroundProgrammed cell death protein-1/programmed cell death ligand-1 (PD-1/PD-L1) inhibitors therapy is now a routine scheme in cancers. However, the effect of preexisting autoantibodies on the safety and efficacy of PD-1/PD-L1 inhibitors in cancer patients is not well understood.MethodsThe pres...

Cijeli opis

Spremljeno u:
Bibliografski detalji
Glavni autori: Hui Tang, Ruixuan Geng, Xiuxiu Xu, Yingyi Wang, Jiaxin Zhou, Shulan Zhang, Lin Zhao, Mei Guan, Chunmei Bai
Format: Artigo
Jezik:Inglês
Izdano: Frontiers Media S.A. 2022-05-01
Serija:Frontiers in Immunology
Teme:
programmed cell death-1
antinuclear antibody
anti-Ro52 antibody
antithyroid antibody
immune-related adverse events
Online pristup:https://www.frontiersin.org/articles/10.3389/fimmu.2022.893179/full
Oznake: Dodaj oznaku
Bez oznaka, Budi prvi tko označuje ovaj zapis!

Similar Items